Full Press Release Details
ChromaDex Corp. and Nestl Health Science Enter Global
Commercial License and Supply Agreement for TRU
ChromaDex Corporation and
Nestl Health Science agreement includes global commercial
license and supply agreement for ingredient sales of TRU
NIAGEN for certain products within the medical
nutrition and consumer health categories.
ANGELES, Calif., December 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex
Corp. (NASDAQ:CDXC) announced today it entered into a license and
supply agreement with Nestl Health Science (NHSc), a global
leader pioneering quality science-based nutritional health
solutions. The agreement provides NHSc the exclusive right to
include CDXC's patented nicotinamide riboside ingredient TRU
NIAGEN in NHSc branded medical nutrition, and co-exclusive
rights to include TRU NIAGEN in certain products within the
consumer health category. The territories in the agreement include
North America, Europe, Latin America, Australia, Japan, and New
ingredient NIAGEN is sold directly to consumers as TRU
NIAGEN , which is backed by clinical and scientific research
establishing its safety and efficacy at elevating the coenzyme
nicotinamide adenine dinucleotide (NAD) in humans. NAD is an
important metabolite involved in virtually every metabolic process
in the body, most notably energy metabolism and cell
Health Science is a blue chip global company whose expertise in
consumer health products is matched by their exceptional
science, said Rob Fried, CEO of ChromaDex. We believe
Nestl Health Science's portfolio with TRU NIAGEN
will substantially advance their already strong market position.
Importantly, this partnership will help educate people on the
importance of elevating NAD levels with TRU NIAGEN . We are
proud to be in business with Nestl and look forward to a
long, mutually beneficial relationship.
Behar, CEO of Nestl Health Science, stated, We are
quite impressed with the science supporting TRU NIAGEN , and
the excellent work done by the team of professionals at ChromaDex.
We see this innovation as an important element of our product
portfolio. We are confident that TRU NIAGEN combined with our
Nestl Health Science products and supported by strong
scientific and clinical evidence will provide consumers the
opportunity to improve the health of their cells with the power of
the terms of the agreement,
NHSc will make an upfront payment of $4 million. CDXC will receive
certain commercial milestone payments related to the sale of TRU
NIAGEN to NHSc as well as tiered royalties.
additional information on the science supporting TRU NIAGEN
visit www.truniagen.com.
is a branded dietary
supplement brought to market by key nicotinamide riboside innovator
and patent holder, ChromaDex. NIAGEN
nicotinamide riboside (NR),
also supplied by ChromaDex, is the sole active ingredient in TRU
Multiple clinical trials demonstrate NIAGEN
is proven to boost NAD
(nicotinamide adenine dinucleotide) levels, which decline with age.
has twice been successfully
reviewed under FDA's new dietary ingredient
( NDI ) notification program and has also been
successfully notified to the FDA as generally recognized as safe
Corp. is an integrated, global nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with
leading universities and research institutions worldwide to uncover
the full potential of NAD and identify and develop novel,
science-based ingredients.
Its flagship ingredient, NIAGEN nicotinamide
riboside, sold directly to consumers as TRU
is backed with clinical and scientific research, as well as
extensive IP protection. TRU
helping the world AGE BETTER .
ChromaDex maintains a website at www.chromadex.com
regularly posts copies of its press releases as well as additional
and financial information about the Company.
Forward-Looking Statements:
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities and Exchange Act of 1934, as amended. Statements that
are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year
ended December 30, 2017, ChromaDex's Quarterly Reports on Form 10-Q
and other filings submitted by ChromaDex to the SEC, copies of
which may be obtained from the SEC's website at www.sec.gov.
Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof. ChromaDex provided research
materials and a portion of the grant funding as a collaborator for
ChromaDex Media Contact:
Worsham, Director of Strategic Partnerships
ChromaDex Investor Relations Contact:
Gerber, Sr. Director of FP&A and Investor